In Medtech, Real-World Evidence is Moving Beyond Theory to Regulatory Use

article image

This year’s annual meeting of ISPOR highlighted efforts to incorporate RWE as a standard tool in regulatory evaluation of medical devices, aided by the rapid digitization of healthcare data and its tremendous potential to reset how FDA calculates risk in assessing device innovation.

The enormous, messy process of optimizing healthcare data that we are amassing at unfathomable rates is well underway.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: